You are here:
LinkedIn-button

News

Check here for our latest news

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable…

  • Additional pre-clinical data of Avacc 10® indicate reduction in upper respiratory tract viral load and cross neutralization of variants of concern
  • Avacc 10® toxicology data support the start of a phase I clinical trial in Q4 2022
Read more

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…

  • Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
  • ALS vaccine is targeting the most common genetic ALS variant
  • 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene
Read more

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced…

  • Publication annual report 2021
  • Appointment of a Chief Business Officer
  • Appointment of a Director vaccine process development
  • Chief Financial Officer joins the Board of Directors
Read more

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…

  • Avacc 3 has significant advantages over existing whooping cough vaccines
  • Second major OMV platform licensing agreement with pharmaceutical company
  • Over 24 million cases of whooping cough per year world-wide
Read more

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur Bilthoven, the Netherlands, and Paris, France, 22 March 2022 – Intravacc, a world leader in translational research and development of preventive…

  • Data published in the prestigious journal ACS Central Science of the American Chemical Society
  • Preclinical and clinical batches complying with ICH guidelines and WHO recommendations
  • Phase I clinical study showed vaccine was safe and well tolerated
  • Phase II clinical studies ongoing in endemic countries
Read more

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine Bilthoven, the Netherlands, 5 January 2022 – Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today…

  • Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
  • No use of mRNA or vector technology
  • Better and direct immunization of mucosa against multiple corona viruses
  • Intravacc focuses on preclinical and process development research and GMP vaccine production
  • Financing of clinical trial study made possible in part by Dutch governmental body Top Consortium for Knowledge and Innovation (TKI)
Read more
LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.